Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

J Feld

Showing results (441-450 of 451) with videos related to

Pageof 46
Sort By:
The American Journal of Gastroenterology|July 4, 2020
Goals of Treatment for Improved Survival in Primary Biliary Cholangitis: Treatment Target Should Be Bilirubin Within the Normal Range and Normalization of Alkaline PhosphataseCarla F Murillo Perez, Maren H Harms, Keith D Lindor, et al.
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association|September 17, 2025
Association Between Sustained Virological Response and Adverse Liver-related Events in Patients With Decompensated Hepatitis C Virus CirrhosisLisa M van Velsen, Lisette A P Krassenburg, Grishma Hirode, et al.
Gastroenterology|April 10, 2017
Efficacy of 8 Weeks of Sofosbuvir, Velpatasvir, and Voxilaprevir in Patients With Chronic HCV Infection: 2 Phase 3 Randomized TrialsIra M Jacobson, Eric Lawitz, Edward J Gane, et al.
The Lancet. Respiratory Medicine|February 8, 2021
Peginterferon lambda for the treatment of outpatients with COVID-19: a phase 2, placebo-controlled randomised trialJordan J Feld, Christopher Kandel, Mia J Biondi, et al.
Gastroenterology|August 3, 2019
Direct-Acting Antiviral Therapy for Hepatitis C Virus Infection Is Associated With Increased Survival in Patients With a History of Hepatocellular CarcinomaAmit G Singal, Nicole E Rich, Neil Mehta, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|June 17, 2022
Oncology clinical trial disruption during the COVID-19 pandemic: a COVID-19 and cancer outcomes studyZ Bakouny, C Labaki, S Bhalla, et al.
The New England Journal of Medicine|January 25, 2018
Glecaprevir-Pibrentasvir for 8 or 12 Weeks in HCV Genotype 1 or 3 InfectionStefan Zeuzem, Graham R Foster, Stanley Wang, et al.
Gastroenterology|January 21, 2019
Direct-Acting Antiviral Therapy Not Associated With Recurrence of Hepatocellular Carcinoma in a Multicenter North American Cohort StudyAmit G Singal, Nicole E Rich, Neil Mehta, et al.
The New England Journal of Medicine|February 13, 2023
Early Treatment with Pegylated Interferon Lambda for Covid-19Gilmar Reis, Eduardo A S Moreira Silva, Daniela C Medeiros Silva, et al.
Medrxiv : the Preprint Server for Health Sciences|July 20, 2021
Genetic regulation of <i>OAS1</i> nonsense-mediated decay underlies association with risk of severe COVID-19A Rouf Banday, Megan L Stanifer, Oscar Florez-Vargas, et al.
Pageof 46

Showing results (441-450 of 451) with videos related to

Sort By:
Pageof 46
The American Journal of Gastroenterology|July 4, 2020
Goals of Treatment for Improved Survival in Primary Biliary Cholangitis: Treatment Target Should Be Bilirubin Within the Normal Range and Normalization of Alkaline PhosphataseCarla F Murillo Perez, Maren H Harms, Keith D Lindor, et al.
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association|September 17, 2025
Association Between Sustained Virological Response and Adverse Liver-related Events in Patients With Decompensated Hepatitis C Virus CirrhosisLisa M van Velsen, Lisette A P Krassenburg, Grishma Hirode, et al.
Gastroenterology|April 10, 2017
Efficacy of 8 Weeks of Sofosbuvir, Velpatasvir, and Voxilaprevir in Patients With Chronic HCV Infection: 2 Phase 3 Randomized TrialsIra M Jacobson, Eric Lawitz, Edward J Gane, et al.
The Lancet. Respiratory Medicine|February 8, 2021
Peginterferon lambda for the treatment of outpatients with COVID-19: a phase 2, placebo-controlled randomised trialJordan J Feld, Christopher Kandel, Mia J Biondi, et al.
Gastroenterology|August 3, 2019
Direct-Acting Antiviral Therapy for Hepatitis C Virus Infection Is Associated With Increased Survival in Patients With a History of Hepatocellular CarcinomaAmit G Singal, Nicole E Rich, Neil Mehta, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|June 17, 2022
Oncology clinical trial disruption during the COVID-19 pandemic: a COVID-19 and cancer outcomes studyZ Bakouny, C Labaki, S Bhalla, et al.
The New England Journal of Medicine|January 25, 2018
Glecaprevir-Pibrentasvir for 8 or 12 Weeks in HCV Genotype 1 or 3 InfectionStefan Zeuzem, Graham R Foster, Stanley Wang, et al.
Gastroenterology|January 21, 2019
Direct-Acting Antiviral Therapy Not Associated With Recurrence of Hepatocellular Carcinoma in a Multicenter North American Cohort StudyAmit G Singal, Nicole E Rich, Neil Mehta, et al.
The New England Journal of Medicine|February 13, 2023
Early Treatment with Pegylated Interferon Lambda for Covid-19Gilmar Reis, Eduardo A S Moreira Silva, Daniela C Medeiros Silva, et al.
Medrxiv : the Preprint Server for Health Sciences|July 20, 2021
Genetic regulation of <i>OAS1</i> nonsense-mediated decay underlies association with risk of severe COVID-19A Rouf Banday, Megan L Stanifer, Oscar Florez-Vargas, et al.
Pageof 46